Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast
Genocea Biosciences (NASDAQ: GNCA) will host its third quarter 2021 corporate update on October 28th at 8:30 a.m. E.T. Participants can join the conference by calling (844) 826-0619 domestically or (315) 625-6883 internationally, using conference ID 8729366. The event will also be available via a live audio webcast on their investor relations page. A replay will be accessible approximately two hours post-event for 90 days. Genocea focuses on developing innovative cancer immunotherapies through its ATLAS™ platform, identifying tumor antigens to optimize targeted therapies.
- None.
- None.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October 28th at 8:30 a.m. E.T.
Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 8729366. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.
About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. We are conducting a Phase 1/2a clinical trial for GEN-011, our investigational adoptive T cell therapy comprising neoantigen-targeted peripheral cells. We continue to monitor patients in our phase 1/2a clinical trial for GEN-009, our investigational neoantigen vaccine. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2020 and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Genocea assumes no duty to update forward-looking statements, except as may be required by law.
| Investor Contact: Dan Ferry 617-430-7576 daniel@lifesciadvisors.com | Media Contact: Sarah O’Connell soconnell@vergescientific.com |
FAQ
What is the date of Genocea Biosciences' third quarter 2021 update?
How can I access the Genocea Biosciences conference call?
Is there a live webcast for the Genocea Biosciences update?
How long will the replay of the Genocea Biosciences event be available?
What does the ATLAS™ platform of Genocea Biosciences do?
